Medytox Raises Daewoong Damages Claim to 500 Billion Won
Medytox officially announced on Sept. 3 that it had submitted an application to amend the purport of the claim and the cause of action in the appellate trial of its lawsuit seeking an injunction against trade secret infringement and damages against Daewoong Pharmaceutical and others, which is underw
On September 3, Medytox announced it had submitted a revised claim in the ongoing lawsuit against Daewoong Pharmaceutical for trade secret infringement and damages. The updated claim amount now stands at 500 billion won, reflecting the expanded scope of the lawsuit.
Medytox stated that the revised claim amount takes into account the additional sales volume and revenue of Daewoong Pharmaceutical's infringing product, identified during the appellate proceedings, as well as the expanded damages calculation period and relevant laws on enhanced damages. These enhanced damages provisions under the Unfair Competition Prevention Act allow for compensation of up to three times the damages incurred after July 9, 2019, and up to five times the damages incurred after August 21, 2024.
Among the 500 billion won "explicit partial claim," Medytox emphasized that this represents a portion of the total potential compensation calculated so far, and damages incurred after August 1, 2025 were not included in this calculation. The company plans to continue taking legal measures to protect its intellectual property and trade secrets.
Medytox's official explained that the claim revision reflects the additional sales data and damages calculation period identified in the appellate trial, making the scope of the claim more realistic. They stressed that as Medytox's core technological assets, the strain and manufacturing process are the result of long-term research and development, and they presented the necessary arguments and evidence to protect the company's rights and interests.
Meanwhile, Daewoong Pharmaceutical responded by stating, in a regulatory filing on September 2, that it plans to actively respond to the lawsuit through its legal representative.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
